185490 — EyeGene Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapSucker Stock

Annual income statement for EyeGene, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	4,245	3,363	3,242	5,293	3,125
Cost of Revenue
Gross Profit	1,938	1,553	1,504	2,746	1,887
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	11,078	17,643	40,104	28,925	30,289
Operating Profit	-6,832	-14,279	-36,862	-23,632	-27,164
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-8,740	-15,313	-34,653	-27,657	-22,430
Provision for Income Taxes
Net Income After Taxes	-8,740	-14,863	-34,569	-26,489	-22,430
Minority Interest
Net Income Before Extraordinary Items
Net Income	-8,740	-14,863	-34,569	-25,953	-21,106
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-8,740	-14,863	-34,569	-25,953	-21,106
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-773	-959	-1,902	-1,224	-970
Dividends per Share